CA3108236A1 - Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors - Google Patents

Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors Download PDF

Info

Publication number
CA3108236A1
CA3108236A1 CA3108236A CA3108236A CA3108236A1 CA 3108236 A1 CA3108236 A1 CA 3108236A1 CA 3108236 A CA3108236 A CA 3108236A CA 3108236 A CA3108236 A CA 3108236A CA 3108236 A1 CA3108236 A1 CA 3108236A1
Authority
CA
Canada
Prior art keywords
alk
once
egf
antibodies
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3108236A
Other languages
English (en)
French (fr)
Inventor
Erik D'hondt
Miguel Angel Molina-Vila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
In3bio Ltd
Original Assignee
In3bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by In3bio Ltd filed Critical In3bio Ltd
Publication of CA3108236A1 publication Critical patent/CA3108236A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3108236A 2018-08-07 2019-08-07 Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors Pending CA3108236A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862715351P 2018-08-07 2018-08-07
US62/715,351 2018-08-07
US201862727056P 2018-09-05 2018-09-05
US62/727,056 2018-09-05
US201862748772P 2018-10-22 2018-10-22
US62/748,772 2018-10-22
US201862760529P 2018-11-13 2018-11-13
US62/760,529 2018-11-13
US201962822290P 2019-03-22 2019-03-22
US62/822,290 2019-03-22
PCT/IB2019/000905 WO2020030977A2 (en) 2018-08-07 2019-08-07 Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3108236A1 true CA3108236A1 (en) 2020-02-13

Family

ID=68425157

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3108236A Pending CA3108236A1 (en) 2018-08-07 2019-08-07 Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors

Country Status (11)

Country Link
US (1) US12257245B2 (https=)
EP (1) EP3833384A2 (https=)
JP (1) JP2021534094A (https=)
KR (1) KR20210041571A (https=)
CN (1) CN112996534B (https=)
AU (1) AU2019319109A1 (https=)
BR (1) BR112021002145A2 (https=)
CA (1) CA3108236A1 (https=)
IL (1) IL280632A (https=)
MX (1) MX2021001398A (https=)
WO (1) WO2020030977A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒
WO2022256360A1 (en) * 2021-06-02 2022-12-08 Neuvogen, Inc. Tumor cell vaccines
WO2023059801A1 (en) * 2021-10-06 2023-04-13 The Regents Of The University Of Colorado, A Body Corporate Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
MX2024005177A (es) * 2021-10-28 2024-08-27 In3Bio Ltd Métodos de uso de anticuerpos anti-fce para aumentar la actividad de los inhibidores de braf y kras.
TW202339767A (zh) * 2022-01-18 2023-10-16 大陸商齊魯製藥有限公司 螺環芳基磷氧化物與抗ｅｇｆｒ抗體的聯用藥物組合物及其用途
WO2024017352A1 (zh) * 2022-07-22 2024-01-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
WO2024249331A1 (en) * 2023-05-26 2024-12-05 The Board Of Regents Of The University Of Texas System Combined rtk and alk inhibition in rtk driven cancers
KR20250120789A (ko) 2024-02-02 2025-08-11 제이투에이치바이오텍 (주) E3 리가제 리간드 화합물, alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
AU2012312515A1 (en) * 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
JP6016953B2 (ja) 2012-03-06 2016-10-26 セファロン、インク． 二重のａｌｋおよびｆａｋ阻害剤としての縮合二環式２，４−ジアミノピリミジン誘導体
CA2882759C (en) * 2012-08-31 2018-11-20 The Regents Of The University Of Colorado Detection of the ntrk1-mprip gene fusion for cancer diagnosis
WO2015148904A1 (en) * 2014-03-28 2015-10-01 Driver Group Methods for predicting egfr tyrosine kinase inhibitor efficacy
KR102359214B1 (ko) * 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
US12595297B2 (en) 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
KR20180011839A (ko) * 2015-06-08 2018-02-02 제넨테크, 인크. 항-ox40 항체를 이용한 암의 치료 방법
HK1251474A1 (zh) * 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
CN111246878A (zh) 2017-07-18 2020-06-05 因斯瑞拜奥有限公司 合成蛋白及其治疗用途
RU2654695C1 (ru) 2017-07-28 2018-05-22 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") 8-(1-{ 4-{ (5-Хлор-4-{ (2-(диметилфосфорил)фенил)амино} пиримидин-2-ил)амино)-3-метоксифенил} пиперидин-4-ил)-1-метил-1,8-диазаспиро(4.5)декан-2-он и его фармацевтически приемлемые соли в качестве модулятора ALK и EGER, предназначенные для лечения рака

Also Published As

Publication number Publication date
WO2020030977A2 (en) 2020-02-13
CN112996534A (zh) 2021-06-18
BR112021002145A2 (pt) 2021-12-14
US12257245B2 (en) 2025-03-25
CN112996534B (zh) 2025-11-18
US20200046690A1 (en) 2020-02-13
KR20210041571A (ko) 2021-04-15
MX2021001398A (es) 2021-08-16
JP2021534094A (ja) 2021-12-09
AU2019319109A1 (en) 2021-02-25
WO2020030977A3 (en) 2020-06-18
IL280632A (en) 2021-03-25
EP3833384A2 (en) 2021-06-16

Similar Documents

Publication Publication Date Title
US12257245B2 (en) Methods and compositions for inhibition of EGF/EGFR pathway in combination with anaplastic lymphoma kinase inhibitors
US20250312348A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
US12258389B2 (en) Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
CA3078806A1 (en) Combination of a parp inhibitor and a pd-1 axis binding antagonist
AU2018241774A1 (en) Combination of an anti-PD-L1 antibody and a DNA-PK inhibitor for the treatment of cancer
TW201938165A (zh) 治療癌症的方法及組合療法
TW202537643A (zh) 抗體-藥物結合物之用途
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
US20220378891A1 (en) Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
CN113271948B (zh) 治疗癌症的联合疗法
CN111246881B (zh) Pd-1抗体用于治疗肿瘤的用途
EP4422757A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
US20260115267A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
US20190358320A1 (en) Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240731

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240731

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240731

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240802

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241120

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250422

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260129

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260129